RVC Biofund Portfolio Company to Contribute to Development of Cancer Therapy
Published: Thursday, February 21, 2013 Last Updated: Thursday, February 21, 2013
The investment committee of RVC Biofund has approved the investment in Andrus Reo, a recently established startup which will conduct phase III clinical trials for an antineoplastic drug in Russia and the CIS.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.